To the Editor:—
Success with human renal homografts in identical twins with renal failure and the development of better immunosuppressive techniques have resulted in more widespread application of this experimental mode to the treatment of end-stage kidney disease.1-3 An increasing number of recipients with kidneys from related and unrelated donors are achieving one-year survival.1The source of donor kidneys has been a major concern because of a logical reluctance to subject healthy, living donors to a procedure with inherent immediate and potential long-range risks. To date, there have been no reports of serious sequelae in a living donor, but their occurrence would seem to be inevitable.The use of cadaver organs offers an acceptable alternative to living donors and has been attempted in a number of centers.1 It has become apparent that such usage presents many problems including the medico-legal aspects, organ preservation, investigation of histocompatibility, and
McIntosh DA, McPhaul JJ, Peterson EW, et al. Homotransplantation of a Cadaver Neoplasm and a Renal Homograft. JAMA. 1965;192(13):1171–1173. doi:10.1001/jama.1965.03080260059024
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: